NUTRITION IN RETT SYNDROME

RETT 综合征的营养

基本信息

  • 批准号:
    6241059
  • 负责人:
  • 金额:
    $ 5.01万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-09-01 至 1998-08-31
  • 项目状态:
    已结题

项目摘要

Somatic growth failure is a major aspect of the developmental arrest of Rett syndrome (RS). Although reduced dietary energy intake may account for somatic growth failure, nutritional repletion does not normalize this problem. This project will examine metabolic and hormonal factors that may provide clues to the pathophysiology of somatic growth arrest in RS girls. We HYPOTHESIZE that, in the presence of positive energy balance, altered partitioning of protein and calcium balance, i.e., increased body protein degradation relative to synthesis, decreased intestinal absorption and increased urinary excretion of calcium, in the presence of reduced serum IGF-1 levels, are the mechanisms that account for persistent somatic growth failure in RS girls. The OBJECTIVE of this proposal is to identify the metabolic and/or hormonal mechanisms by which the partitioning of protein and calcium balance is altered and to estimate the contribution of these abnormalities to the protein and calcium requirements of RS girls. The SPECIFIC AIMS of this proposal are 1) to compare in RS and healthy girls: a) rates of body protein degradation, synthesis, leucine oxidation, net retention, the splanchnic extraction of lysine, and urea production; b) rates of intestinal absorption and diet- and bone-derived urinary excretion of calcium; c) insulin, IGF-1, cortisol, growth hormone, and osteocalcin levels; and 2) to determine if the abnormalities of: a) protein and calcium metabolism; b) hormone profiles, and c) somatic growth of RS girls can be reversed with dietary protein and calcium intakes in excess of recommended allowances. Two groups of SUBJECTS, RS and healthy girls, will be studied at baseline. Subsequently, RS girls will be randomized into one of two dietary protein/calcium treatment groups or a no-treatment group and studied after 1 yr. Untreated RS girls will be treated thereafter and studied a third time 1 yr. later. METHODS: Rates of body protein synthesis, degradation, net retention, and urea production will be determined using primed, constant infusions of [1-/13C] leucine, [d/4,4,5,5] lysine, and [15/N/2] urea. Rates of intestinal absorption and diet- or bone-derived urinary losses of calcium will be determine by intravenous/oral single bolus doses of 42/Ca and 46/Ca. Insulin, IGF-1, growth hormone, cortisol, and osteocalcin levels will be determined by radioimmunoassay. Body composition will be determined by 40/K counting and DEXA. Analysis of covariance without/with repeated measures will be used to determine significant differences in outcome variables between RS and healthy girls and among the high vs. usual vs. no dietary protein/calcium treatment groups. SIGNIFICANCE: The information obtained from this study will provide further insight into the metabolic and/or hormonal mechanisms that lead to somatic growth arrest in RS. A better understanding of the partitioning of dietary protein and calcium balance during conditions of altered growth will permit a more rational approach to nutritional intervention and improve the clinical outcome and quality of life of RS girls.
体细胞生长衰竭是发育阻滞的一个主要方面

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KATHLEEN J MOTIL其他文献

KATHLEEN J MOTIL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KATHLEEN J MOTIL', 18)}}的其他基金

RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORAL CALCIUM SUPPLEMENTATION FOR OSTEO
口服钙补充剂治疗 OSTEO 的随机、安慰剂对照试验
  • 批准号:
    8356674
  • 财政年份:
    2010
  • 资助金额:
    $ 5.01万
  • 项目类别:
RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORALCALCIUM SUPPLEMENTATION FOR OSTEO
口服钙补充剂治疗 OSTEO 的随机、安慰剂对照试验
  • 批准号:
    8166676
  • 财政年份:
    2009
  • 资助金额:
    $ 5.01万
  • 项目类别:
RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORALCALCIUM SUPPLEMENTATION FOR OSTEO
口服钙补充剂治疗 OSTEO 的随机、安慰剂对照试验
  • 批准号:
    7950621
  • 财政年份:
    2008
  • 资助金额:
    $ 5.01万
  • 项目类别:
THE NATURAL HISTORY OF OSTEOPENIA IN GIRLS WITH RETT SYNDROME
RETT 综合征女孩骨质减少的自然史
  • 批准号:
    7605849
  • 财政年份:
    2007
  • 资助金额:
    $ 5.01万
  • 项目类别:
THE NATURAL HISTORY OF OSTEOPENIA IN GIRLS WITH RETT SYNDROME
RETT 综合征女孩骨质减少的自然史
  • 批准号:
    7374953
  • 财政年份:
    2005
  • 资助金额:
    $ 5.01万
  • 项目类别:
THE NATURAL HISTORY OF OSTEOPENIA IN GIRLS WITH RETT SYNDROME
RETT 综合征女孩骨质减少的自然史
  • 批准号:
    7206753
  • 财政年份:
    2004
  • 资助金额:
    $ 5.01万
  • 项目类别:
NUTRITION IN RETT SYNDROME
RETT 综合征的营养
  • 批准号:
    6306259
  • 财政年份:
    1999
  • 资助金额:
    $ 5.01万
  • 项目类别:
NUTRITION IN RETT SYNDROME
RETT 综合征的营养
  • 批准号:
    6278025
  • 财政年份:
    1997
  • 资助金额:
    $ 5.01万
  • 项目类别:
ENERGY EXPENDITURE IN HEALTHY CHILDREN AND CHILDREN WITH RETT SYNDROME
健康儿童和患有 RETT 综合征的儿童的能量消耗
  • 批准号:
    6277982
  • 财政年份:
    1997
  • 资助金额:
    $ 5.01万
  • 项目类别:
OROMOTOR AND GASTROINTESTINAL DYSFUNCTION IN RETT SYNDROME
RETT 综合征中的口腔运动和胃肠功能障碍
  • 批准号:
    6247883
  • 财政年份:
    1997
  • 资助金额:
    $ 5.01万
  • 项目类别:

相似海外基金

Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10004277
  • 财政年份:
    2020
  • 资助金额:
    $ 5.01万
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10475298
  • 财政年份:
    2020
  • 资助金额:
    $ 5.01万
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10693904
  • 财政年份:
    2020
  • 资助金额:
    $ 5.01万
  • 项目类别:
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10013749
  • 财政年份:
    2020
  • 资助金额:
    $ 5.01万
  • 项目类别:
Study on how anticonvulsants affect car driving
抗惊厥药如何影响汽车驾驶的研究
  • 批准号:
    20K17977
  • 财政年份:
    2020
  • 资助金额:
    $ 5.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10266034
  • 财政年份:
    2020
  • 资助金额:
    $ 5.01万
  • 项目类别:
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10475109
  • 财政年份:
    2020
  • 资助金额:
    $ 5.01万
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10248384
  • 财政年份:
    2020
  • 资助金额:
    $ 5.01万
  • 项目类别:
Prevention of neuropathic pain by antidepressants and anticonvulsants: in vivo patch-clamp analysis
抗抑郁药和抗惊厥药预防神经性疼痛:体内膜片钳分析
  • 批准号:
    24592355
  • 财政年份:
    2012
  • 资助金额:
    $ 5.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Anticonvulsants, ischemic seizures and regeneration in the immature brain
抗惊厥药、缺血性癫痫发作和未成熟大脑的再生
  • 批准号:
    8492175
  • 财政年份:
    2009
  • 资助金额:
    $ 5.01万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了